Today, the FDA announced the first approved treatment for Niemann-Pick Type C (NPC) disease: an oral medication named Miplyffa (arimoclomol). Sean Kassen, director of the Ara Parseghian Medical Research Fund at the University of Notre Dame, said this represents the beginning of a new and hopeful era for NPC families.

During the 2024 fiscal year, researchers at the University of Notre Dame submitted 1,310 proposals for external research funding for a total amount of $1.016 billion — the first time the University has surpassed the billion-dollar mark for proposals. In addition, the University received 829 separate awards — the largest...